Chemed (NYSE:CHE) Issues FY 2024 Earnings Guidance

Chemed (NYSE:CHE) issued an update on its FY 2024 earnings guidance on Tuesday morning. The company provided EPS guidance of 23.000-23.150 for the period, compared to the consensus EPS estimate of 23.580. The company issued revenue guidance of -. Chemed also updated its FY24 guidance to $23.00-$23.15 EPS.

Chemed Price Performance

CHE stock traded down $4.66 on Friday, hitting $535.58. 102,188 shares of the company were exchanged, compared to its average volume of 84,744. Chemed has a twelve month low of $525.36 and a twelve month high of $654.62. The business’s fifty day moving average is $586.09 and its two-hundred day moving average is $568.84. The stock has a market capitalization of $8.06 billion, a price-to-earnings ratio of 27.32, a price-to-earnings-growth ratio of 2.18 and a beta of 0.44.

Chemed (NYSE:CHE) last issued its quarterly earnings results on Tuesday, October 29th. The company reported $5.64 EPS for the quarter, missing the consensus estimate of $5.76 by ($0.12). Chemed had a return on equity of 27.86% and a net margin of 12.69%. The company had revenue of $606.18 million for the quarter, compared to analyst estimates of $612.22 million. During the same period last year, the company posted $5.32 EPS. The business’s revenue for the quarter was up 7.4% on a year-over-year basis. Equities research analysts expect that Chemed will post 21.77 earnings per share for the current year.

Insiders Place Their Bets

In other Chemed news, CEO Kevin J. Mcnamara sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, August 5th. The shares were sold at an average price of $569.63, for a total transaction of $1,139,260.00. Following the completion of the sale, the chief executive officer now directly owns 105,735 shares in the company, valued at $60,229,828.05. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Chemed news, CEO Kevin J. Mcnamara sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, August 5th. The shares were sold at an average price of $569.63, for a total transaction of $1,139,260.00. Following the completion of the sale, the chief executive officer now directly owns 105,735 shares in the company, valued at $60,229,828.05. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Andrea R. Lindell sold 831 shares of the business’s stock in a transaction that occurred on Friday, August 16th. The stock was sold at an average price of $571.51, for a total transaction of $474,924.81. Following the sale, the director now owns 5,725 shares of the company’s stock, valued at approximately $3,271,894.75. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 7,144 shares of company stock worth $4,141,679 over the last ninety days. 3.32% of the stock is owned by company insiders.

About Chemed

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.